Two high-profile partnerships signal that Abridge, the AI medical-scribe startup, is moving aggressively beyond its core documentation tool and into broader healthcare infrastructure.
According to Fierce Healthcare, Nvidia and Abridge are collaborating to develop a healthcare-specific AI model — a step beyond the general-purpose large language models that most clinical AI tools currently rely on. A purpose-built model trained on medical data could reduce the errors and hallucinations that make clinicians wary of trusting AI outputs in high-stakes settings.
The Nvidia tie-up is not Abridge's only major announcement. According to Healthcare Dive, the company is also partnering with pharmaceutical giant Eli Lilly, though the publication did not detail the scope of that collaboration. Together, the deals suggest Abridge is positioning itself as a platform, not just a transcription service — attracting partners across both the chip-making and drug-development sides of the industry.
Abridge built its reputation as an AI scribe: it listens to doctor-patient conversations and automatically drafts clinical notes, saving physicians significant administrative time. Expanding into model development with Nvidia would give it more control over the underlying technology and potentially open licensing or infrastructure revenue streams.
The broader significance is this: when the company supplying the world's AI chips co-develops a model with a healthcare startup, it signals that medicine is now central — not peripheral — to the next wave of AI commercialization.